Versant Venture Capital VI, L.P. sold LENZ

September 18, 2025 · Form 4 insider transaction

Versant Venture Capital VI, L.P. sold 49,479 shares of LENZ Therapeutics, Inc. at $41.59 per share, a transaction worth $2.06M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 4 days after the transaction.

Direction
Disposed (sell-side)
Shares
49,479
Price
$41.59
Total value
$2.06M
Role10% owner
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateSeptember 18, 2025
Filing dateSeptember 22, 2025
Shares owned after1,224,718
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.; These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

View the original Form 4 on SEC EDGAR